

Certificate of Mailing

Date of Deposit October 31, 2001

Label Number: EL874187525US

I hereby certify under 37 C.F.R. § 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" with sufficient postage on the date indicated above and is addressed to BOX PATENT APPLICATION, Assistant Commissioner for Patents, Washington, D.C. 20231.

Marcellus Green  
Printed name of person mailing correspondence

Muller  
Signature of person mailing correspondence

APPLICATION  
FOR  
UNITED STATES LETTERS PATENT

APPLICANT : JACK W. SZOSTAK, DAVID S. WILSON, AND  
ANTHONY D. KEEFE

TITLE : STREPTAVIDIN-BINDING PEPTIDES AND USES  
THEREOF

SEARCHED  
INDEXED  
MAILED  
OCT 31 2001

STREPTAVIDIN-BINDING PEPTIDES AND USES THEREOF

5

Cross-reference to Related Applications

This application claims benefit from U.S. Provisional application serial no. 60/244,541, filed October 31, 2000, hereby incorporated by reference.

10

Statement as to Federally Sponsored Research

This invention was funded by grant number R01GM53936 from the National Institutes of Health and grant number NCC-2-1069 from NASA. The government may have certain rights in the invention.

215  
20  
15  
10  
5  
F01 F02 F03 F04 F05 F06 F07 F08 F09 F01 F02 F03 F04 F05 F06 F07 F08 F09

Background of the Invention

In general, the invention features novel compounds and methods for purifying or detecting proteins of interest.

Determining the enzymatic activity, binding specificity, or three-dimensional structure of a protein often requires the purification of the protein from a complex mixture of other components, such as compounds present in a cell lysate or *in vitro* translation extract. With the number of known proteins increasing dramatically as a result of whole genome sequencing projects, it has become crucial to find alternatives to traditional, time-consuming monoclonal antibody production for generating affinity reagents for the detection and purification of proteins. In addition, purifying a novel protein using traditional column chromatography methods often requires much trial and error to develop a purification protocol that results in the recovery of the protein in high yield and purity.

Thus, purification methods are needed that may be generally applied to proteins of interest, that utilize inexpensive reagents, and that result in highly purified protein without requiring multiple chromatography steps.

5

### Summary of the Invention

The purpose of the present invention is to provide improved reagents for the purification, detection, or quantitation of proteins of interest. In particular, the high affinity, streptavidin-binding peptides of the present invention may be used as affinity tags for the purification of fusion proteins containing proteins of interest.

10

Accordingly, in a first aspect, the invention provides a peptide which binds streptavidin with a dissociation constant less than 10  $\mu$ M (that is, binds streptavidin more tightly than a  $K_D$  of 10  $\mu$ M) and which is not disulfide bonded or cyclized. Preferably, the dissociation constant is equal to or less than 5  $\mu$ M, 1  $\mu$ M, 100 nM, 50 nM, 25 nM, 10 nM, or even 5 nM. In one preferred embodiment, the dissociation constant is less than 10  $\mu$ M, 5  $\mu$ M, 1  $\mu$ M, 100 nM, 50 nM, or 25 nM; and greater than 0.01 nM, 0.1 nM, 1 nM, 5 nM, or 10 nM. In another preferred embodiment, the value of the dissociation constant is contained in one of the following ranges: 5  $\mu$ M to 1  $\mu$ M, 1  $\mu$ M to 100 nM, 100 nM to 50 nM, 50 nM to 25 nM, 25 nM to 10 nM, 10 nM to 5 nM, 5 nM to 1 nM, or 5 nM to 0.1 nM, inclusive.

15  
20  
25

20

25

In a related aspect, the invention provides a peptide which binds streptavidin with a dissociation constant less than 10  $\mu$ M. The amino acid sequence of the peptide does not contain an HPQ, HPM, HPN, or HQP motif. Preferably, the dissociation constant is equal to or less than 5  $\mu$ M, 1  $\mu$ M, 100 nM, 50 nM, 25 nM, 10 nM, or 5 nM. In one preferred embodiment, the dissociation constant is less than 10  $\mu$ M, 5  $\mu$ M, 1  $\mu$ M, 100 nM, 50 nM, or 25 nM; and greater than 0.01 nM, 0.1 nM, 1 nM, 5 nM, or 10 nM. In another preferred embodiment, the value of the dissociation constant is contained in one of the following ranges: 5  $\mu$ M to 1  $\mu$ M, 1  $\mu$ M to 100 nM, 100 nM to 50 nM, 50 nM to 25 nM, 25 nM to 10 nM, 10 nM to 5 nM, 5 nM to 1 nM, or 5 nM to 0.1 nM, inclusive.

In another related aspect, the invention provides a peptide which binds streptavidin with a dissociation constant less than 23 nM, 10 nM, or 5 nM. In one preferred embodiment, the peptide is disulfide bonded or cyclized. In another preferred embodiment, the dissociation constant is less than 23 nM, 10 nM, or 5 nM; and greater than 0.01 nM, 0.1 nM, or 1 nM. In another preferred embodiment, the value of the dissociation constant is contained in one of the following ranges: 20 nM to 10 nM, 10 nM to 5 nM, 5 nM to 1 nM, or 5 nM to 0.1 nM, inclusive.

In other related aspects, the invention provides nucleic acids encoding the peptides of the present invention, and vectors that include such nucleic acids.

In addition, standard gene fusion techniques may be used to generate fusion nucleic acids that encode fusion proteins which include a peptide of the present invention and a protein of interest. The fusion proteins may be purified, detected, or quantified based on the high affinity of the peptides for streptavidin.

Accordingly, in one such aspect, the invention provides a fusion protein including a protein of interest covalently linked to one of the following peptides: (a) a peptide which binds streptavidin with a dissociation constant less than 10  $\mu$ M and which is not disulfide bonded or cyclized, (b) a peptide which binds streptavidin with a dissociation constant less than 10  $\mu$ M and which does not contain an HPQ, HPM, HPN, or HQP motif, or (c) a peptide which binds streptavidin with a dissociation constant less than 23 nM. In preferred embodiments, the peptide is attached to the amino-terminus or the carboxy-terminus of the protein of interest, or the peptide is positioned between the amino and carboxy-termini of the protein of interest. Preferably, the peptide is linked to the protein of interest by a linker which includes a protease-sensitive site.

In related aspects, the invention provides nucleic acids encoding the fusion proteins of the present invention, and vectors that include these fusion nucleic acids.

In addition, the invention provides a method of producing a fusion protein of the present invention. This method includes transfecting a vector having a

15  
20  
25

nucleic acid sequence encoding the fusion protein into a suitable host cell and culturing the host cell under conditions appropriate for expression of the fusion protein.

The fusion proteins described herein may be used in methods for purifying 5 proteins of interest from samples. Such a method involves expressing the protein of interest as a fusion protein covalently linked to one of the following peptides: (a) a peptide which binds streptavidin with a dissociation constant less than 10  $\mu$ M and which is not disulfide bonded or cyclized, (b) a peptide which binds streptavidin with a dissociation constant less than 10  $\mu$ M and which does not 10 contain an HPQ, HPM, HPN, or HQP motif, or (c) a peptide which binds streptavidin with a dissociation constant less than 23 nM. A sample containing the fusion protein is contacted with streptavidin under conditions that allow complex formation between the fusion protein and streptavidin. The complex is isolated, and the fusion protein is recovered from the complex, thereby purifying the protein of interest from the sample. In one preferred embodiment, the protein of interest is recovered from the fusion protein by cleaving the streptavidin-binding peptide from the fusion protein.

In yet another aspect, the invention provides a method of detecting the presence of a fusion protein of the present invention in a sample. This method includes (a) contacting the sample with streptavidin or a streptavidin-containing compound under conditions that allow complex formation between the fusion protein and either streptavidin or the streptavidin-containing compound; (b) isolating the complex, and (c) detecting the presence of streptavidin or the streptavidin-containing compound in the complex or following recovery from the complex. The presence of streptavidin or the streptavidin-containing compound indicates the presence of the fusion protein in the sample. Preferably, step (c) also involves measuring the amount of streptavidin or the streptavidin-containing compound in the complex or following recovery from the complex. The amount of fusion protein in the sample is correlated with, and may be calculated from, the 20 measured amount of streptavidin. For example, for a fusion protein containing a 25 measured amount of streptavidin. For example, for a fusion protein containing a 30 measured amount of streptavidin. For example, for a fusion protein containing a

peptide that binds one molecule of streptavidin per molecule of peptide, the amount of fusion protein in the sample is predicted to be approximately the same as the amount of streptavidin measured. In one preferred embodiment, the amount of streptavidin is determined using Western or ELISA analysis with an antibody that reacts with streptavidin or that reacts with a compound that is covalently linked to streptavidin. In another preferred embodiment, streptavidin is covalently linked to an enzyme, radiolabel, fluorescent label, or other detectable group, and the amount of streptavidin is determined using standard techniques based on a characteristic of the detectable group such as its enzyme activity, radioactivity, or fluorescence.

In another aspect, the invention features a method of determining the affinity of a compound of interest for a target molecule. The method includes incubating a solution having a compound of interest with a detectable group and a free target molecule under conditions that allow complex formation between the compound of interest and the free target molecule. The solution is contacted with a target molecule immobilized on a solid support under conditions that allow complex formation between the compound of interest and the immobilized target molecule, and the compound of interest bound to the immobilized target molecule is then separated from the compound of interest not bound to the immobilized target molecule. To determine the affinity, either the amount of the compound of interest that is bound to the immobilized target or the amount of the compound of interest not bound to the target molecule is then measured. In yet another preferred embodiment, the steps of this method are repeated one or more times with a different concentration of free target molecule. In other preferred embodiments, both the amount of the compound of interest bound to the immobilized target molecule and the amount of the compound of interest not bound to the immobilized target molecule are measured. In another embodiment, only the amount of the compound of interest that is not bound to the immobilized target molecule is measured. In another embodiment, the target is immobilized on a solid support such as a microtiter plate, a bead, or the matrix of a spin-filter

15  
20  
25  
30

column. In another embodiment, the compound of interest that is bound to the immobilized target molecule is separated from the compound of interest that is not bound to the immobilized target molecule by centrifugation, for example, by spin-filtration or ultracentrifugation. In still other preferred embodiments, the target is a small molecule such as streptavidin, a streptavidin fusion protein, streptavidin covalently bound to an enzyme (*e.g.* horseradish peroxidase or alkaline phosphatase), or a ligand. The compound of interest may be a peptide that binds streptavidin, or may be a fusion protein that includes a peptide that binds streptavidin and a protein of interest. In other embodiments, the compound of interest may be labeled with a detectable group, such as a radiolabel, a fluorescent molecule, or an enzyme.

In preferred embodiments of various aspects of the invention, the amino acid sequence of the peptide includes at least 10, 25, 50, 75, or 100 consecutive amino acids or consists of between 5 and 150, 10 and 100, 20 and 75, or 30 and 50 amino acids, inclusive, of any one of SEQ ID Nos. 1-29 or 35. Preferably, the amino acid sequence of the peptides includes an LPQ, QPQ, EPQ, HPA, HPD, or HPL motif. In other preferred embodiments, the amino acid sequence includes any one of SEQ ID Nos. 1-29 or 35. In still other preferred embodiments, the peptide has an amino acid sequence that is at least 20, 30, 40, 50, 60, 70, 80, 90, 95, or 100% identical to any one of SEQ ID Nos. 1-29 or 35.

It is also contemplated that the affinity of the peptides of the present invention for streptavidin may be increased by incorporating disulfide bonds into, or cyclizing, the peptides. By constraining the peptides, the amount of disorder inherent in the peptides (*i.e.*, entropy) decreases, and thus binding of these peptides to streptavidin may require less energy. It is also contemplated that the three-dimensional structure of peptides of the invention bound to streptavidin may be experimentally determined or modeled based on the known crystal structure of streptavidin and used to determine possible modifications to the peptides that may further improve their affinity for streptavidin.

As used herein, by “nucleic acid” is meant a sequence of two or more

covalently bonded naturally-occurring or modified deoxyribonucleotides or ribonucleotides.

By "peptide" is meant a sequence of two or more covalently bonded naturally-occurring or modified amino acids. The terms "peptide" and "protein" are used interchangeably herein.

5 By "covalently linked" is meant covalently bonded or connected through a series of covalent bonds. A group that is covalently linked to a protein may be attached to the amino-terminus, carboxy-terminus, between the amino- and carboxy-termini, or to a side chain of an amino acid in the protein.

10 By "streptavidin" is meant any streptavidin molecule or fragment thereof or any protein that has an amino acid sequence that is at least 80, 90, 95, or 100% identical to a streptavidin molecule or fragment thereof (see, for example, Haeuptle *et al.* J. Biol. Chem. 258: 305, 1983). A preferred fragment of streptavidin is "core" streptavidin, which is a proteolytic cleavage product of streptavidin (Bayer *et al.* Biochem. J. 259:369-376, 1989). Preferably, a streptavidin molecule or fragment thereof is capable of binding biotin or any other streptavidin-binding molecule. Streptavidin or a streptavidin fragment may be modified chemically or through gene fusion technology or protein synthesis so that it is covalently linked to an enzyme, radiolabel, fluorescent label, or other detectable group. These detectable groups may be used to determine the presence or location of a streptavidin-bound fusion protein in a cell or sample or to quantify the amount of a streptavidin-bound fusion protein, using standard methods.

20 By a "streptavidin-containing compound" is meant any compound that includes streptavidin covalently bound to another molecule. These compounds may, for example, be conjugated to streptavidin through gene fusion technology or protein synthesis and may, for example, be covalently linked to an enzyme, such as horseradish peroxidase or alkaline phosphatase, a fluorescent group, a radiolabel, or any other detectable group.

25 By "free target molecule" is meant a target molecule that is not bound to a solid support.

15  
20  
25  
30

By “cyclized” is meant nonlinear. A peptide may be cyclized by the formation of a covalent bond between the N-terminal amino group of the peptide or the side-chain of a residue and the C-terminal carboxyl group or the side-chain of a residue. For example, a peptide lactam may be formed by the cyclization between the N-terminal amino group or an amino group of an amino acid side-chain and the C-terminal carboxyl group or a carboxyl or amide containing side-chain. Other possible cyclizations include the formation of a thioether by the reaction of a thiol group in a cysteine side-chain with the N-terminal amino group, C-terminal carboxyl group, or the side-chain of another amino acid. A disulfide bond may also be formed between two cysteine residues. As used herein, a “non-cyclized peptide” is a linear peptide that does not have any of the above cyclizations.

By “dissociation constant” is meant the dissociation constant for binding streptavidin as measured using the electrophoretic mobility shift assay described herein. By “less than” a particular dissociation constant is meant capable of binding streptavidin more tightly than the strength of binding represented by a particular dissociation constant.

By “purifying” is meant separating a compound, for example, a protein, from other components that naturally accompany it. Typically, a protein is substantially pure when it is at least 50%, by weight, free from proteins and naturally-occurring organic molecules with which it is naturally associated. Preferably, the protein is at least 75%, more preferably, at least 90%, and most preferably, at least 99%, by weight, pure. In other preferred embodiments, the protein is at least 2, 5, 10, 25, 50, or 100 times as pure as the starting material. Purity may be assayed by any appropriate method, such as polyacrylamide gel electrophoresis, column chromatography, optical density, HPLC analysis, western analysis, or ELISA (see, for example, Ausubel *et al.*, *Current Protocols in Molecular Biology*, John Wiley & Sons, New York, 2000).

By “recovered from the complex” is meant physically separated from the complex of streptavidin and the fusion protein. For example the streptavidin-

15  
20  
25

bound fusion protein may be incubated under conditions that reduce the affinity of the fusion protein for streptavidin (*i.e.*, at low or high salt concentrations or at low or high pH values) or incubated in the presence of molecules that compete with the fusion protein for binding streptavidin. Preferably, either the fusion protein or the streptavidin that has been released from the complex is isolated using standard procedures, such as column chromatography, polyacrylamide gel electrophoresis, HPLC, or western analysis.

The present invention provides a number of advantages related to the detection and purification of proteins of interest. For example, because the present methods do not require the generation of an antibody or other affinity reagent that is specific for each protein of interest, these methods may be universally applied to any protein. In addition, if desired, the streptavidin-binding peptide may be connected to the protein of interest through a protease cleavable linker, allowing removal of the peptide after purification of the fusion protein.

Using the methods described herein, purification of a fusion protein based on its affinity for streptavidin has allowed the isolation of the fusion protein in significantly higher purity than that obtained using a hexahistidine affinity tag or maltose-binding protein affinity tag. Moreover, streptavidin is an inexpensive reagent that may be purchased unmodified or covalently labeled with a detectable group (such as FITC-streptavidin or alkaline phosphatase-conjugated streptavidin) or with a chromatography matrix (such as streptavidin-agarose). The availability of these reagents simplifies methods for detecting and purifying the fusion proteins of the present invention.

In addition, the streptavidin binding peptide-tag are particularly useful when intermediate amounts of protein (~10-500  $\mu$ g) need to be produced and purified in a high throughput manner. For example, highly parallel purification protocols may be performed in 96-well plates using streptavidin-derivatized magnetic beads and streptavidin binding peptide -tagged proteins expressed in *E. coli* or in coupled *in vitro* transcription/translation reactions. This facilitates purification, for example,

for proteomics applications in which thousands of purified proteins need to be generated and purified in parallel.

Other features and advantages of the invention will be apparent from the following detailed description and from the claims.

5

#### Brief Description of the Drawings

Figure 1A is a schematic illustration of an *in vitro* selection process according to the invention, showing the structure of the library and the selection scheme. Members of the DNA library have, from the 5' to 3' end, a T7 RNA polymerase promoter (T7), a tobacco mosaic virus translation enhancer (TMV), a start codon (ATG), 88 random amino acids, a hexahistidine tag (H6), and a 3' constant region (Const).

Figure 1B is a picture of an SDS-PAGE gel of samples from the library at different stages of preparation. The first lane shows the result of translating the mRNA display template with  $^{35}\text{S}$ -methionine. Most of the counts represent free peptide (free pep), but a significant amount of mRNA-peptide covalent fusions are also present (mRNA-pep). There is also another band that is independent of added template (NS, non-specific), and some counts remain in the gel well. The band corresponding to the mRNA-peptide can be shifted to a position slightly higher than that for the free peptide by the addition of RNase A. The remaining lanes show the result of successive oligo-dT and Ni-NTA purifications, and finally reverse transcription (RT).

Figure 2A is a bar graph showing the fraction of  $^{35}\text{S}$  counts from the displayed peptides that bound to streptavidin and eluted with biotin, at each round of selection. Figure 2B is a graph showing the elution profile for the peptide library generated from the output of the seventh round of selection in Figure 2A. The first fraction represents the flow-through. Biotin was added at the point indicated. The plot compares the binding of the intact, reverse-transcribed, displayed peptides (mRNA-pep), the same sample treated with RNase A, and the

15  
20

RNase-treated sample applied to a streptavidin column pre-saturated with biotin (excess biotin was washed away prior to exposing the library to the matrix).

Figure 3 is a list of the sequences of 20 clones from the seventh round of selection (SEQ ID Nos.: 1-20). The "#" column indicates the number of times each sequence was observed. The HPQ sequence is in bold type. Non-random sequences at the termini are underlined. The six C-terminal-most residues are not shown.

Figure 4A is a picture of a native gel showing an electrophoretic mobility shift (EMSA) analysis demonstrating the binding of four different DNA-tagged peptides to streptavidin. The migration of each clone is shown in the absence (-) and presence (+) of 1  $\mu$ M streptavidin. Some of the clones show multiple bands, presumably representing different conformations. The arrows show the position of the gel well, which often contains a fraction of the counts. Figure 4B is a picture of a native gel showing the titration of the full-length clone SB19 with streptavidin. The streptavidin concentration in each lane, from left to right, is: 3.8, 6.6, 10, 15, 23, 35, and 61 nM. Figure 4C is a curve fit of the data shown in Figure 4B (the fraction of peptide bound could not be accurately determined for the point with the lowest concentration of streptavidin). Assuming that the peptide is homogeneous and 100% active, the data from this experiment give a  $K_D$  of 10 nM for the binding of peptide SB19 to streptavidin.

Figure 5 is a list of the sequences of truncation mutants of peptide SB19 (SEQ ID Nos.: 21-29). The full-length (FL), C-terminal deleted (C1-C4), N-terminal deleted (N1-N3), and point mutated (M1) peptide sequences are shown. The "% binding" refers to the performance of these peptides in the streptavidin column-binding assay.

Figure 6A is the nucleotide sequence of the plasmid used for expression of a fusion protein containing a streptavidin-binding peptide (SEQ ID No.: 37). Figure 6B is the amino acid sequence of the encoded protein (SEQ ID No.: 38) which contains, from the amino- to carboxy-terminus, maltose-binding protein, a

15  
16  
17  
18  
19  
20

streptavidin-binding peptide (SEQ ID No.: 35, Fig. 7A), a hexahistidine tag, and another peptide called 2r18-19dN. Figure 6C is the amino acid sequence of 2r18-19dN (SEQ ID No.: 39).

Figure 7A is the amino acid sequence of the streptavidin-binding peptide (SEQ ID No.: 35) used as an affinity tag for the purification of the fusion protein listed in Fig. 6B. This peptide contains the first 38 amino acids of the SB19-C4 peptide (Fig. 5). Figure 7B is a picture of an SDS-PAGE gel showing the purity of the fusion protein after elution from the streptavidin column (lane 2) compared to the purity of the *E. coli* lysate that was applied to the column (lane 1).

Figures 8A-8F are schematic illustrations of the pre-selection method. Figure 8A is an illustration of an mRNA display template terminating in puromycin in which the tobacco mosaic virus translation enhancer sequence (TMV), the initiating methionine codon (AUG), and the sections of the open reading frame encoding the two protein affinity tags (FLAG and His<sub>6</sub>) are labeled. Figure 8B is an illustration of an mRNA display template that is free of frameshifts and premature stop codons and thus encodes a full-length protein containing both affinity tags. Figure 8C illustrates an mRNA display template that has initiated internally and displays the corresponding truncated protein lacking the N-terminal FLAG tag. Figure 8D shows an mRNA display template that has a deletion in its open reading frame and thus displays the corresponding frameshifted protein lacking the C-terminal His<sub>6</sub> tag. Figure 8E illustrates the reverse transcription of the mRNA display template from Fig. 8B that was purified based on the presence of both protein affinity tags in the encoded protein. Figure 8F shows the cleavage sites for Type IIS restriction enzymes which are encoded in each cassette.

Ligation of pre-selected cassettes which have been cleaved with these enzymes yields the full-length DNA library.

Figure 9A is the polynucleotide sequence of the vector encoding a fusion protein containing maltose-binding protein, a streptavidin-binding peptide (SEQ ID No.: 35, Fig. 7A), and a hexahistidine tag. Figure 9B is the amino acid sequence of the encoded fusion protein. The sequence of the streptavidin-binding

5  
10  
15  
20

peptide which contains the first 38 amino acids of the SB19-C4 peptide is underlined.

Figure 10A is a graph of the Biacore (Surface Plasmon Resonance) response units over various lengths of time for the dissociation of streptavidin from the fusion protein listed in Fig. 9B immobilized on a biacore chip. For line “a,” the streptavidin concentration is 23  $\mu$ M; for line “b,” the concentration is 11.5  $\mu$ M, and for line “c,” the concentration is 5.75  $\mu$ M. This data was used to calculate an upper limit of  $2 \times 10^{-3}$ /s for the dissociation rate,  $K_D$  Figure 10B is a graph showing the association and subsequent dissociation of streptavidin from the immobilized fusion protein. For lines “a” through “f,” the streptavidin concentrations are 1.6, 0.8, 0.4, 0.2, 0.1, and 0.05  $\mu$ M, respectively. This data was used to calculate an association rate,  $k_a$ , of  $5 \times 10^4$ /M/s.

Figure 11 is a map of the pTAG2K vector indicating the order of the domains in the multiply-tagged fusion protein it encodes.

Figure 12 is a graph showing a  $K_D$  determination of the streptavidin binding peptides-streptavidin interaction using the Spin-filter Binding Inhibition Assay (SBIA). The labeled streptavidin binding peptide-tagged peptide was incubated with a range of streptavidin concentrations and the amount not complexed was then determined after a short incubation with immobilized streptavidin. This analysis gave a  $K_D$  of 2.5 nM for the interaction of the streptavidin binding peptide sequence with streptavidin.

Figure 13 is a purity assay for a single-step purification of streptavidin binding peptide-tagged (multiply-tagged) protein from lysed cells. Purity is compared to samples processed upon the basis of the His-tag or the maltose-binding protein sequences contained in the same protein. Lanes 1 and 2 show lysed *E. coli* prior to and after IPTG-induction, respectively. Lane 3 shows the soluble fraction of *E. coli* lysate in streptavidin-binding buffer. Lanes 4 through 6 show approximately equal amounts of purified proteins from the elution fractions

15  
16  
17  
18  
19  
20

of the streptavidin binding peptide-tag purification, the His-tag purification, and the maltose-binding protein purification, respectively.

Figure 14 illustrates a detection of a streptavidin binding peptide-tagged protein with streptavidin-derivatized horseradish peroxidase. The left-hand panel shows the Coomassie Brilliant Blue staining of an SDS-Tricine PAGE gel of the purified streptavidin binding peptide-tagged (multiply-tagged) protein and an *E. coli* extract. These same samples were also run on a different portion of the same gel and then transferred to a nitrocellulose membrane. The right-hand panel shows the result of the probing of this membrane with streptavidin-derivatized horseradish peroxidase. The only observed signal is for the streptavidin binding peptide-tagged protein, with no staining of other proteins in the extract.

Figure 15 is a graph showing a  $K_D$  determination of a streptavidin binding peptide-streptavidin interaction. The y axis shows the fraction of surface-bound peptide that is competed by the free streptavidin. This analysis gave a  $K_D$  of 2.4 nM for the interaction of the streptavidin binding peptide sequence with streptavidin.

#### Detailed Description

The present methods stem from the discovery of peptides that have unusually high affinities for streptavidin ( $K_D$  of less than 10  $\mu\text{M}$ ). These peptides were selected from a library of randomized, non-constrained peptides using the mRNA display method. The high affinity of the selected peptides was particularly surprising, given the fact that non-constrained linear peptide libraries generally do not yield high affinity ligands to proteins, except in cases where the protein normally functions in peptide recognition (Clackson *et al.*, Trends Biotech 12:173-184 (1994); Katz, Annu. Rev. Biophys. Biomol. Struct. 26:27-45, 1997). Many other peptides with high affinity for streptavidin may be isolated using the mRNA display method or any other selection method, such as ribosome display (Roberts,

Curr. Opin. Chem. Biol. 3(3):268-73, 1999), or phage display (U.S. Patent No. 5,821,047).

The binding characteristics of exemplary selected streptavidin-binding peptides are described in Table 1, and the sequences of these peptides are listed in Fig. 3. The first column of Table 1 lists the peptide name (SB1 - SB20). For comparison, a non-selected sequence with two HPQ motifs spaced by 19 residues (called “non-selected”) is listed in row one. SB19-C4 is a truncation mutant of peptide SB19, described below. The peptides are grouped according to the number of HPQ and similar tripeptide motifs they possess. The second column shows the number of tripeptide motifs in each peptide, and the number of amino acid residues separating them. The third column represents the percentage of peptide binding and specifically eluting from a streptavidin column. This percentage ranged from 8.3% to as high as 88% for the selected peptides, compared to only 0.16% for the control, non-selected peptide with two HPQ motifs.

The fourth column shows the  $K_D$ , when known, for the interaction between streptavidin and the peptides, as measured in the EMSA assay described herein. The standard deviation in the  $K_D$  is shown in the fifth column, based on the number of independent measurements (n, shown in parentheses). The dissociation constant ranged from 110 nM for peptide SB5 to 4.8 nM for peptides SB2.

15  
20  
25  
30  
35  
40  
45  
50  
55  
60  
65  
70  
75  
80  
85  
90  
95  
100

**Table 1**

Peptide	Structure	% binding and eluting	K <sub>D</sub> (nM)	Standard deviation (n)
5	Non-selected <b>HPQ</b> 19 <b>HPQ</b>	0.16		
10	<i>Two HPQ motifs</i>			
	SB1 <b>HPQ</b> 19 <b>HPQ</b>	86	50	5.7 (4)
	SB2 <b>HPQ</b> 19 <b>HPQ</b>	48	4.8	0.91 (8)
	SB3 <b>HPQ</b> 23 <b>HPQ</b>	20		
	SB4 <b>HPQ</b> 43 <b>HPQ</b>	49		
	SB5 <b>HPQ</b> 52 <b>HPQ</b>	72	110	22 (6)
15	<i>One HPQ and one similar tripeptide motif</i>			
	SB6      HPL 4 <b>HPQ</b>	49		
	SB7      HPD 7 <b>HPQ</b>	28		
	SB8 <b>HPQ</b> 12 HPL	27		
	SB9 <b>HPQ</b> 12 HP	64		
20	SB10 <b>HPQ</b> 21 QPQ	15		
	SB11 <b>HPQ</b> 28 HPA	68		
	SB12 <b>HPQ</b> 30 EPQ	73		
	SB13 <b>HPQ</b> 32 EPQ	64		
	SB14 <b>HPQ</b> 43 HPL	11		
25	SB15     QPQ 50 <b>HPQ</b>	44	92	16 (4)
	SB16 <b>HPQ</b> 74 LPQ	50		
	<i>One HPQ motif</i>			
	SB17	8.3		

SB18	58		
SB19	85	10	1.8 (10)
SB19 - C4	88	4.9	0.88 (10)

5 *No HPQ motif*

SB20	HPL	34
------	-----	----

To further characterize the binding of the selected peptides to streptavidin, truncation mutants for peptide SB19 were constructed to determine which regions were necessary for high affinity streptavidin-binding (Fig. 5). Deletion of up to 56 residues had no observable effect on the binding strength. For example, peptide SB19-C4 retained only the first 38 residues from the selected construct (plus the C-terminal sequence MMSGGCKLG, SEQ ID No.: 36) and had a dissociation constant of 4.9 nM for streptavidin (Table 1). In contrast, N-terminal truncation mutations (N1-N3) resulted in a lower percentage of the encoded peptide specifically eluting from the streptavidin column (0.058 to 69% for the truncation mutants compared to 85% for full length SB19). These results suggested that the determinants for binding streptavidin were spread throughout the N-terminal 38 residues of the SB19 peptide.

High affinity streptavidin-binding peptides, such as those shown in Table 1, have a number of uses. For example, these peptides may be used for protein purification by expressing a protein of interest as a fusion protein joined to one or more of the streptavidin-binding peptides of the invention. In one such purification method, a sample containing the fusion protein is incubated with immobilized streptavidin. Proteins with no or weak affinity for streptavidin are washed away, and the fusion protein is then selectively eluted from the streptavidin matrix by addition of biotin, a biotin analog, another streptavidin-binding peptide, or any compound that competes with the fusion protein for

binding to the matrix. Alternatively, the fusion protein may be eluted from the matrix by increasing or decreasing the pH of the buffer applied to the matrix.

As described in detail below, this general protocol was used in a one-step purification of a fusion protein containing a streptavidin-binding peptide from an *E. coli* extract, resulting in a high yield of very pure protein. This fusion protein contained the first 38 amino acids of the SB19-C4 peptide, which due to its small size was not expected to affect the three-dimensional structure or activity of the covalently-linked protein of interest. Purification of fusion proteins containing other streptavidin-binding peptides of the present invention may be performed similarly.

In addition, various modifications of the above purification protocol would be apparent to one skilled in the art (see, for example, Ausubel *et al.*, *supra*), and such modifications are included in the invention. In particular, use of the streptavidin-binding peptides as affinity tags is desirable for high throughput protein production and purification. For example, purification of fusion proteins in a multi-well format may be conducted using magnetic streptavidin beads that are washed and eluted robotically. The methods of the present invention may also be adapted to purify fusion proteins from *in vitro* translation mixtures or from other extracts, such as those from prokaryotic, yeast, insect, or mammalian cells, using standard techniques. If necessary, avidin may be added to the extract to bind any free biotin in the extract before contacting a sample from the extract with streptavidin. Allowing any free biotin to bind avidin may prevent biotin from competing with the streptavidin-binding peptides for binding to streptavidin.

If desired, the presence of a fusion protein of the invention in a sample may be detected by incubating the fusion protein with streptavidin (*i.e.*, unlabeled streptavidin or streptavidin that is labeled with a detectable group) under conditions that allow streptavidin to bind the fusion protein. Preferably, the unbound streptavidin is separated from the streptavidin-bound fusion protein. Then, the streptavidin that is bound to the fusion protein is detected. Alternatively, the streptavidin bound to the fusion protein is physically separated from the fusion

15  
20  
25  
30  
35  
40  
45  
50  
55  
60  
65  
70  
75  
80  
85  
90  
95  
100  
105  
110  
115  
120  
125  
130  
135  
140  
145  
150  
155  
160  
165  
170  
175  
180  
185  
190  
195  
200  
205  
210  
215  
220  
225  
230  
235  
240  
245  
250  
255  
260  
265  
270  
275  
280  
285  
290  
295  
300  
305  
310  
315  
320  
325  
330  
335  
340  
345  
350  
355  
360  
365  
370  
375  
380  
385  
390  
395  
400  
405  
410  
415  
420  
425  
430  
435  
440  
445  
450  
455  
460  
465  
470  
475  
480  
485  
490  
495  
500  
505  
510  
515  
520  
525  
530  
535  
540  
545  
550  
555  
560  
565  
570  
575  
580  
585  
590  
595  
600  
605  
610  
615  
620  
625  
630  
635  
640  
645  
650  
655  
660  
665  
670  
675  
680  
685  
690  
695  
700  
705  
710  
715  
720  
725  
730  
735  
740  
745  
750  
755  
760  
765  
770  
775  
780  
785  
790  
795  
800  
805  
810  
815  
820  
825  
830  
835  
840  
845  
850  
855  
860  
865  
870  
875  
880  
885  
890  
895  
900  
905  
910  
915  
920  
925  
930  
935  
940  
945  
950  
955  
960  
965  
970  
975  
980  
985  
990  
995  
1000

protein and then detected, using standard methods. For example, to detect streptavidin that is bound to the fusion protein or that has been separated from the fusion protein, Western or ELISA analysis may be performed using an antibody that reacts with streptavidin or that reacts with a compound that is covalently linked to streptavidin. If streptavidin is covalently linked to an enzyme, radiolabel, 5 fluorescent label, or other detectable group, the amount of streptavidin may be determined using standard techniques based on a characteristic of the detectable group such as its enzyme activity, radioactivity, or fluorescence (see, for example, Ausubel *et al.*, *supra*). Alternatively, streptavidin may be contacted with a 10 streptavidin-binding compound that is covalently linked to an enzyme, radiolabel, fluorescent label, or other detectable group, and the detectable group may be assayed as described herein.

We have also developed an improved method to generate synthetic DNA libraries encoding full-length proteins, which may be used in a variety of selection methods to isolate proteins with desired binding affinities or activities. The generation of libraries of proteins containing a desired number of amino acids is often limited by the number of internal initiation events that result in truncated proteins and the number of frameshifts that result in either premature stop codons or the removal of desired stop codons. For example, during solid phase DNA synthesis, insertions and deletions which cause frameshifts may occur due to imperfect coupling and capping efficiencies. In addition, the random regions in DNA templates may encode stop codons, resulting in premature truncation of the encoded protein. To address these problems, we have developed a method in which small DNA cassettes are synthesized, and an *in vitro* selection using the 20 mRNA display technology is performed to enrich the library of DNA cassettes for sequences encoding two protein affinity tags. These DNA cassettes lack frameshifts and premature stop codons. The selected DNA cassettes are then cleaved with restriction enzymes and ligated to generate the full-length DNA library (Figs. 8A-8F) (Cho *et al.*, J. Mol. Biol. 297:309-319, 2000).

15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

In one preferred embodiment of this method, mRNA display templates that contain a translation enhancer sequence operably-linked to an open reading frame and that terminate in puromycin are generated as described previously (Cho *et al.*, *supra*). The open reading frame encodes two different protein affinity tags, such as a FLAG tag and a hexahistidine tag. Preferably, one of the tags is located at the amino-terminus of the encoded peptide, and the other tag is located at the carboxy-terminus. The mRNA display templates are *in vitro* translated to generate mRNA displayed peptides (Cho *et al.*, *supra*). mRNA displayed peptides encoded by templates that do not contain frameshifts or premature stop codons should contain both affinity tags. In contrast, templates that contain frameshifts or premature stop codons encode peptides without the C-terminal affinity tag (Fig. 8D). Additionally, mRNA display templates that initiate internally produce peptides without the N-terminal affinity tag (Fig. 8C). The library of mRNA displayed peptides is enriched for peptides containing both affinity tags by purification of the mRNA displayed peptides based on the presence of these tags (see, for example, Ausubel *et al.*, *supra*). For example, the mRNA displayed peptides may be applied to a matrix designed to bind peptides containing one of the affinity tags, and the mRNA display peptides without the affinity tag are washed away. The mRNA display peptides containing the affinity tag are then eluted and applied to a second matrix designed to bind the other affinity tag. The mRNA display peptides recovered from this purification step are enriched for members containing both affinity tags and thus for full-length peptides. These mRNA displayed peptides are reversed transcribed to generate double-stranded DNA. The amplified DNA is then cleaved by restriction enzymes. Preferably, this restriction digestion removes the sequences encoding the affinity tags from the DNA cassettes. The cleaved DNA cassettes are then ligated to generate the full-length DNA templates.

The experiments described above were carried out as follows.

**Generation of a Streptavidin-Binding Peptide Library**

The mRNA display method for selecting peptides or proteins of interest takes advantage of the translation-terminating antibiotic puromycin, which functions by entering the A site of ribosomes and forming a covalent bond with the nascent peptide. By covalently attaching puromycin to the 3' end of an mRNA, a covalent link between a polypeptide and its encoding message can be achieved *in situ* during *in vitro* translation (Roberts *et al.*, Curr. Opin. Struct. Biol. 9:521-529, 1999; Liu *et al.*, Methods Enzymol. 318:268-293, 2000). These mRNA-peptide fusions can then be purified and subjected to *in vitro* selection, yielding the isolation of novel peptide ligands.

A DNA library encoding polypeptides of 108 amino acids was synthesized as described (Cho *et al.*, *supra*). The library consisted of short cassettes concatamerized together. Each cassette encoded a random peptide with a pattern of polar *versus* non-polar amino acid side chains compatible with forming an amphipathic  $\alpha$ -helix or  $\beta$ -strand (Cho *et al.*, *supra*). The random region was 88 amino acids long, followed by a C-terminal invariant region containing a hexahistidine tag (Fig. 1A).

The library had a complexity of  $2.4 \times 10^{14}$  at the DNA level. It was transcribed using T7 RNA polymerase (Fig. 1A), after which a "linker" oligonucleotide was added to the 3' end using T4 DNA ligase as described (Liu *et al.*, *supra*; Cho *et al.*, *supra*). The linker consisted of a 21 nucleotide long dA stretch, followed by a polyethylene glycol linker, followed by the sequence dA-dC-dC-puromycin (Liu *et al.*, *supra*).

This puromycin-terminated mRNA was translated *in vitro*, using the Ambion (Austin, TX) *in vitro* translation kit under standard conditions for capped mRNA. The 10 mL reaction mixture was supplemented with 2 mCi  $^{35}\text{S}$ -methionine and a total methionine concentration of 10  $\mu\text{M}$ . The reaction mixture also included 300 nM of the library of puromycin-linked mRNA molecules. After

2015 RELEASE UNDER E.O. 14176

1 hour at 30°C, MgCl<sub>2</sub> and KCl were added to 20 and 710 mM, respectively, and the reaction mixture was further incubated at room temperature for five minutes to increase the yield of displayed peptides. This *in vitro* translation produced 1.2 x 10<sup>14</sup> polypeptides linked *via* the puromycin moiety to their encoding mRNAs.

5 These mRNA displayed peptides were then purified on oligo-dT cellulose (which binds to the oligo-dA sequence in the linker) to remove polypeptides not fused to mRNA. For this purification procedure, the reaction mixture was diluted 10-fold into oligo-dT-binding buffer (1M NaCl, 50 mM HEPES, 10 mM EDTA, 0.25% Triton X-100, and 5 mM 2-mercaptoethanol at pH 7.9) and 80 mg oligo-dT cellulose (type 7, Amersham-Pharmacia, Piscataway, NJ) and incubated with agitation at 4°C for 30 minutes. The mixture was applied to a column (Poly-Prep chromatography column, Biorad, Hercules, CA), drained, washed with 10 mL oligo-dT-binding buffer, washed with 10 mL oligo-dT-wash buffer (300 mM NaCl, 20 mM HEPES, 1 mM EDTA, 0.25% Triton X-100, and 5 mM 2-mercaptoethanol at pH 7.9), and washed with 1 mL of 0.5x oligo-dT-wash buffer. The mRNA-displayed peptides were eluted with 4.5 mL water plus 5 mM 2-mercaptoethanol into tubes containing Triton X-100 and bovine serum albumin (BSA, New England Biolabs, Beverly, MA) at final concentrations of 0.15% and 15 µg/mL, respectively.

10 20 25 The mRNA-displayed peptides that eluted from the oligo-dT cellulose column were further purified on Ni-NTA agarose, which binds to the hexahistidine tags on the polypeptides, to remove any mRNA not fused to polypeptides. The eluted fractions from the oligo-dT cellulose purification were exposed to 0.5 mL Ni-NTA-agarose (Qiagen, Valencia, CA) in Ni-binding buffer [6 M guanidinium chloride, 0.5 M NaCl, 100 mM sodium phosphate, 10 mM Tris(hydroxymethyl)aminomethane, 0.1% Triton X-100, 5 mM 2-mercaptoethanol, 4 µg/mL tRNA (Boehringer-Mannheim, Indianapolis, IN), and 5 µg/mL BSA at pH 8.0] and incubated for 30 minutes at room temperature. The matrix was then drained, washed with 12 column volumes Ni-binding buffer, and eluted with the

same buffer plus 100 mM imidazole. Eluted fractions were combined and de-salting using two successive NAP columns (Amersham-Pharmacia, Piscataway, NJ) equilibrated in 1 mM Tris(hydroxymethyl)aminomethane, 0.01% Triton X-100, 50  $\mu$ M EDTA, 0.5 mM 2-mercaptoethanol, 0.5  $\mu$ g/mL tRNA (Boehringer-Mannheim, Indianapolis, IN), and 50  $\mu$ g/mL BSA at pH 7.6.

5 The mRNA portion was then reverse transcribed using Superscript II (Gibco BRL, Rockville, MD) according to the manufacturers instructions, except that the mRNA concentration was about 5 nM and the enzyme concentration was 1 U/ $\mu$ L. To ensure a high yield in the reaction, a mixture of two primers were  
10 used: 1  $\mu$ M of "splint" from the splinted ligation (Cho *et al.*, *supra*), and 1  $\mu$ M of the 3' PCR primer. After 30 minutes at 42°C, the temperature of the reaction mixture was raised to 50° for 2 minutes, and then cooled over 5 minutes to room temperature to allow gradual peptide folding. Finally, the contents were de-salting using NAP columns and subjected to scintillation counting. By comparing the  $^{35}$ S counts of the purified, reverse transcribed mRNA-peptide fusions to the  $^{35}$ S-methionine stock and taking into consideration the total methionine concentration in the translation reaction (10  $\mu$ M), the number of displayed peptides in this sample was determined to be  $6.7 \times 10^{12}$ . This number also represents the complexity of the library, since it contained virtually no redundancy (the complexity of puromycin-linker template used in the translation exceeds the number of recovered displayed peptides by a factor of about 35).

20 Samples from the synthesis and purification of the mRNA displayed peptides were run on an SDS-PAGE gel, as shown in Fig. 1B.

25 Selection of Streptavidin-Binding Peptides

For selection of peptides with high affinity for streptavidin, the above mRNA displayed peptide library was incubated with immobilized streptavidin (Ultralink immobilized streptavidin plus, about 4 mg/mL; Pierce, Rockford, IL) in streptavidin-binding buffer under reducing conditions (40 mM Tris(hydroxymethyl)aminomethane, 300 mM KCl, 2 mM EDTA, 0.1% Triton X-

30

100, 5 mM 2-mercaptoethanol, 100  $\mu$ g/mL BSA, and 1  $\mu$ g/mL tRNA at pH 7.4). The amount of gel used was 0.5 mL in a total volume of 5.5 mL. After incubating for 20 minutes at room temperature, the contents were loaded onto a disposable chromatography column, drained, washed with 14 column volumes of 5 streptavidin-binding buffer, and eluted with five successive aliquots, at 10 minutes intervals, of streptavidin-binding buffer plus 2 mM D-biotin (Sigma, St. Louis, MO) (Fig. 1A). The fraction of the library that survived this purification was 0.08%. Elution fractions were combined, de-salted on NAP columns, and then 10 PCR-amplified to regenerate the double-stranded DNA library using the described conditions and primers in a 8 mL reaction mixture (Cho *et al.*, *supra*).

This concluded the first round of selection, and the remaining six rounds followed the same protocol except that the translation was scaled down 10-fold, and the number of column volumes for washing the streptavidin column was increased (32 volumes for round 2; 40 volumes for rounds 3, 4 and 6; and 25 volumes for rounds 5 and 7). The streptavidin-binding selection for rounds 5 and 7 was performed directly on the streptavidin-column eluate from the preceding selection rounds, without intervening amplification (the biotin was removed by three successive passages through NAP columns). PCR products amplified after the seventh selection round were cloned using the TOPO TA cloning kit (Invitrogen, Carlsbad, CA), following the manufacturer's protocol. The fraction of the library that bound and eluted from the streptavidin column increased in each round, reaching 61% at round seven (Fig. 2A).

#### Characterization of the Selected Library

25 The eluate from the seventh round of selection was amplified by PCR. The resulting PCR DNA was used to synthesize a library of displayed peptides to confirm that the displayed peptides, rather than the RNA or DNA portion of the library constructs, were responsible for the interaction with streptavidin. Treatment of the library with RNase A did not reduce the extent of 30 binding/elution from the matrix (Fig. 2B). Also, biotin-saturated streptavidin

bioRxiv preprint doi: <https://doi.org/10.1101/2015.07.20.031515>; this version posted July 20, 2015. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a [aCC-BY-ND 4.0 International license](https://creativecommons.org/licenses/by-nd/4.0/).

showed no binding to the peptide library (Fig. 2B). These results demonstrated that the interaction of the selected peptides with the streptavidin matrix was specific for the unligated protein, rather than for any other component of the matrix.

5

#### Sequence Analysis of Selected Peptides

Thirty-three randomly chosen clones from the PCR DNA from round seven were chosen for sequencing. Twenty different sequences were observed (Fig. 3). Surprisingly, all 20 sequences were frame-shifted from the intended frame (frame 1) to frame 3 by deletion of two nucleotides or addition of one nucleotide. The designed pattern of polar and non-polar residues was therefore discarded, leaving an unpatterned, essentially random sequence. Prior to the selection, about half of the library members were in frame 1 throughout their entire open reading frames (Cho *et al.*, *supra*). Frame 3 appears to have been enriched over frame 1 due to the increased frequency of the sequence HPQ. Frame 1 has a low incidence (1:45,000 library members) of the sequence HPQ due to the designed polar/non-polar pattern. By contrast, frame 3 had a much higher expected incidence of the HPQ sequence (1:64), similar in frequency to that of a library of the same length and with equal mixtures of all four nucleotides at each position (1:193). Also, frame 3 was rich in histidine, thus allowing retention on the Ni-NTA column. The Ni-NTA purification protocol was intended to eliminate library mRNA molecules not displaying peptide, but was not performed under sufficiently stringent conditions so as to eliminate peptides with small numbers of histidines. Frame 2 had a high incidence of stop codons.

25 Nineteen of the 20 clones had at least one HPQ motif, and five clones contained two such motifs (Table 1). The clones were organized according to the number of times the HPQ and related tripeptide motifs occur (Table 1). The number of amino acids between the two motifs, when present, ranged from four to 74.

30

Binding Affinities of Peptides

To rapidly assay each of the 20 selected peptides to determine their affinity for streptavidin, a new method for preparing, tagging and purifying the peptides was employed. For generation of the DNA-tagged peptides, plasmids containing single inserts were used as templates for PCR-amplification using the same 5' PCR 5 primer as described for the library construction (Cho *et al.*, *supra*), and a new 3' primer (5'-ATAGCCGGTGCCAAGCTTGCAGCCGCCAGACCAAGT-3'; SEQ ID No. 30), which altered the 3' RNA sequence to

ACUGGUCUGGCGGCCUGCAAGCUUGGCACCGGCUAU (SEQ ID No. 31).

10 This sequence was designed to anneal to the photo-crosslinking linker, which has the sequence 5'-psoralen-TAGCCGGTG-A17-CC-puromycin-3', in which the underlined bases are 3'-methoxy nucleotides and the remaining bases are deoxynucleotides (the oligonucleotide was synthesized using reagents from Glen Research, Sterling, VA). This new primer changed the constant C-terminal peptide sequence from WSGGCHHHHHSSA (SEQ ID No. 32) to WSGGCKLGTGY 15 (SEQ ID No. 33), of which the last three amino acids may not be translated because they are annealed to the linker. Each DNA template was transcribed and gel purified as described (Cho *et al.*, *supra*), and then incubated with the psoralen 20 linker under the following conditions: 2  $\mu$ M mRNA, 4  $\mu$ M linker, 50 mM Tris(hydroxymethyl)aminomethane, 200 mM KCl, and 10 mM spermidine at pH 7.4 and 70°C for 2 minutes, and then cooled to 4°C over 5 minutes. Samples were then placed in the cold room in a 96 well plate (50  $\mu$ L/well), one inch above which was suspended a UV lamp (366 nm, Ultraviolet Products, Inc., San Gabriel, CA, model number UVL-21) for 15 minutes. Then, the reactions mixtures were de- 25 salted using a G-50 Sephadex spin column (Boehringer Mannheim, Indianapolis, IN). The translation/display reactions and oligo-dT-purification were carried out as above. Finally, RNase A (200 ng/mL, 10 minutes, room temperature) was added to degrade the mRNA, leaving peptides fused to a short DNA oligonucleotide. Complete degradation was confirmed by SDS-PAGE analysis.

PCT/US2015/044607

The resulting purified DNA-tagged peptides (DTP) were analyzed in a streptavidin column-binding assay, in which ~500 pM  $^{35}\text{S}$ -labeled DTP were mixed with 50  $\mu\text{L}$  of the streptavidin matrix in streptavidin-binding buffer, in a total volume of 300  $\mu\text{L}$ , and incubated for 10 minutes at room temperature with agitation. Then, the contents were loaded onto a chromatography column. The column was drained and washed with 80 column volumes of streptavidin-binding buffer, and then eluted with three consecutive aliquots (3 column volumes each) of streptavidin-binding buffer plus 2 mM biotin over a 15 minute period. All fractions (flow-through, washes, elutions, and irreversibly bound counts) were analyzed by scintillation counting to determine the fraction of DTP that bound streptavidin and eluted with biotin (Table 1). The non-selected clone in which two HPQ motifs (separated by 19 amino acids) were introduced encoded the sequence

MDEAHPQAGPVDQADARLVQQGALQHHHPQGDRMMMSGGCKLGTGY  
(SEQ ID No. 34), in which the underlined portions are identical the HPQ regions of clone SB2.

The results of this analysis are shown in Table 1. For comparison, two HPQ motifs, separated by 19 residues, were introduced into a control, unselected member of the library. The low percentage of this control peptide that specifically eluted from the streptavidin column (0.16%) indicated that the presence of two HPQ motifs was not sufficient for high affinity binding. In contrast, a greater percentage of the selected peptides (8.3 to 88%) was retained on the column during the washing step and then specifically eluted with biotin.

The dissociation constants of the selected peptides for streptavidin were measuring using an electrophoretic mobility shift assay (EMSA). In this assay, DTP's were incubated with varying amounts of pure streptavidin (Pierce Immunopure Streptavidin, Rockford, IL) in streptavidin-binding buffer plus 5% glycerol to increase the density of the solution so that it could collect at the bottom of the gel well. After incubating at room temperature for 20 minutes, the reactions

2015/07/24 14:52:00

mixtures were moved into the cold room, where they remained for 10 minutes before being carefully loaded onto a 10% polyacrylamide:bisacrylamide (37.5:1, National Diagnostics, Atlanta, GA) gel (thickness 0.7 mm, height 16 cm, width 18 cm) containing 2X TBE, 0.1% Triton X-100 and 5% glycerol. The gel, which had been pre-run for 30 minutes at 13 watts, and the running buffer were pre-cooled to 4°C. Then, the gel was run in the cold room at 13 watts, which increased the temperature of the gel to about 20°C. The gel was run for 45 to 120 minutes, depending on the mobility of the particular DTP. Then, the gel was fixed in 10% acetic acid and 10% methanol for 15 minutes, transferred to electrophoresis paper (Ahlstrom, Mt. Holly Springs, PA), dried, and analyzed using a PhosphorImager (Molecular Dynamics, Sunnyvale, CA).

The short DNA oligonucleotide tag on the DTP's allowed them to migrate in a native gel, and the addition of unlabeled ligand (i.e., streptavidin) caused a mobility shift for several of the clones. The concentration of DTPs was less than 1 nM in each titration, and thus the dissociation constant ( $K_D$ ) can be approximated by the concentration of streptavidin that results in half of the DTP being mobility-shifted. To determine the  $K_D$ , several different measurements were taken in the range of 25-75% of DTP bound (values outside of this range were unreliable due to background and close proximity of the bound and unbound bands in the gel). The  $K_D$  was determined using the equation  $K_D = [\text{streptavidin}]^*R$ , where R is the ratio of unbound to bound DTP (ratio of unshifted to shifted band). Independent measurements on gels prepared at different times were used for each clone (the number of different measurements, n, is shown in Table 1). Streptavidin concentrations were measured by  $\text{UV}_{282}$ , using the molar extinction coefficient of 57,000 per monomer.

Examples of these mobility shifts in the presence of streptavidin are shown in Fig. 4A. Some clones showed either no shift or poorly defined bands, suggesting that the lifetime of these complexes was too short for detection using this method. We chose five of the most well behaved clones and quantitatively

15  
20  
25  
30  
35  
40  
45  
50  
55  
60  
65  
70  
75  
80  
85  
90  
95

examined their mobility shifts in response to a range of streptavidin concentrations. An example of a streptavidin titration experiment for peptide SB19 is shown in Fig. 4B, and the data is graphed in Fig. 4C. The dissociation constants for the clones ranged from 110 nM to less than 5 nM (Table 1). These surprisingly high affinities were comparable to those for monoclonal antibody-antigen interactions, demonstrating that even random, non-constrained peptide libraries can be a source of avid ligands to proteins that do not normally function in peptide binding.

10 Dissection of Clone SB19

Clone SB19 possessed only one HPQ motif, bound to 85% in the column binding assay, and had a  $K_D$  for streptavidin of 10 nM (Table 1). A series of C-terminal truncation constructs (C1-C4) were constructed and assayed in the streptavidin column-binding assay (Fig. 5). C-terminal truncation analysis of clone SB19 was performed using standard methods by amplifying the clone with the original 5' primer and a series of 3' primers that truncated the sequence at various positions and also replaced two codons (encoding Asp and Trp) in the C-terminal constant region with methionine codons to increase the  $^{35}\text{S}$ -incorporation. Analogous primers were used for the N-terminal truncation analysis, except that no change was made in the N-terminal constant sequence.

20 Deletion of up to 56 residues had no observable effect on the binding strength. Peptide SB19-C4 retained only the first 38 residues from the selected construct (plus the C-terminal MMSGGCKLG sequence, SEQ ID No. 36). Mutating the HPQ motif to HGA reduced the activity by three orders of magnitude (compare construct C4 to M1). Results from the N-terminal truncation constructs (N1-N3) suggested that binding determinants were spread throughout the N-terminal 38 residues of peptide SB19. Of the peptides tested, SB19-C4 was therefore the minimal peptide retaining full activity in this assay. EMSA analysis of peptide SB19-C4 confirmed high affinity streptavidin-binding, but a fraction

(13%) of the peptide was inactive even at streptavidin concentrations  $>1 \mu\text{M}$ . The majority (87%), however, had an apparent  $K_D$  of 4.9 nM after correction for the amount of inactive peptide.

5 Purification of Fusion Protein Containing Streptavidin-Binding Peptide

A fusion protein containing the first 38 amino acids of the SB19-C4 streptavidin-binding peptide (Fig. 7A) was expressed in *E. coli* and then purified from the cell lysate. For the expression of the fusion protein, BL21 (DE3) cells were transformed with a plasmid containing a Maltose Binding Protein--  
10 Streptavidin-binding Peptide--His<sub>6</sub>—Protein of Interest insert (Figure 11) which encodes a fusion protein containing, from the amino- to carboxy-terminus, maltose-binding protein, the first 38 residues of the SB19-C4 sequence, a hexahistidine tag, and another peptide called 2r18-19dN (Figs. 6A-6C). This insert was constructed using standard molecular biology techniques (see, for example, Ausubel *et al., supra*). Each of these domains of the fusion protein is separated by a few amino acids to allow proper folding of the domains.

A kanamycin-resistant colony was selected and grown overnight in 10 ml LB media with 50 mg/liter kanamycin at 37°C. This starter culture was diluted 100-fold into 1000 ml LB with 50 mg/liter kanamycin, and the culture was grown at 37°C to OD<sub>600</sub> of 1.6-1.8 at 37°C. Expression of the fusion protein was induced by addition of 1mM IPTG, and the culture was grown for another two hours. The cells were pelleted by centrifugation at 3000-5000 X g for 20 minutes. The pelleted cells were resuspended in 5% of the original volume of a buffer appropriate for the subsequent affinity purification method. For purification on an amylose column the cells were resuspended in 1 mM EDTA and MBP buffer (10 mM HEPES.HCl, 10 mM HEPES.Na<sup>+</sup>, 200 mM KCl, 0.25% w/w Triton X-100, and 10 mM BME at pH 7.4) and frozen slowly at -20°C overnight.

15  
20

The sample was thawed in the morning and sonicated on ice. The cell lysate was obtained by collection of the supernatant after centrifugation at 14,000 X g for 20 minutes at 4°C.

To purify the fusion protein, the cell lysate was applied to a column containing immobilized streptavidin, with a capacity of about 1 mg/ml, that had been washed with eight column volumes of MBP buffer. Then, the column was washed with 12 column volumes of MBP buffer. The fusion protein was eluted with MBP buffer containing 2 mM biotin. Samples of the cell lysate and eluted protein were analyzed by SDS-PAGE on an 8% gel (Fig. 7B). The lane containing the purified protein had a band of the expected size. No other bands were observed, except for a faint band of slightly higher mobility (Fig. 7B). This band was probably a degradation product of the fusion protein that was missing a few amino acids from either the amino- or carboxy-terminus but retained the streptavidin-binding peptide and thus retained the ability to bind the streptavidin column. Thirty percent of the fusion protein loaded onto a column containing immobilized streptavidin was recovered after washing the column with 12 column volumes of buffer. Thus, the high affinity of the fusion protein for streptavidin allowed extensive washing of the column to remove contaminating proteins, while retaining a significant amount of the desired fusion protein.

More stringent conditions eliminated the contaminating protein of higher molecular weight. The soluble fraction of lysed induced cells was prepared in Streptavidin-binding buffer (SBB: 300 mM KCl, 40 mM Tris(hydroxymethyl) amino methane, 5 mM 2-mercaptoethanol, 2 mM EDTA, 0.1% Triton-X 100, pH 7.4) as described above. This sample (e.g., 79 mg net weight cells in 1 ml SBB) was applied directly to the immobilized streptavidin matrix (e.g., column volume 100  $\mu$ l; Ultralink Immobilized Streptavidin Plus, Pierce, Rockford IL) and then incubated at 4°C for 30 minutes. The matrix was then washed with 40 column volumes of SBB and then eluted with 3 successive 2 column volume aliquots of SBB containing 2 mM biotin for 10 minutes each. Samples of each of the lysed

15  
20  
25

uninduced and lysed induced cells, the soluble fraction, and the elution fraction were then analyzed on an 8% SDS-Tricine PAGE gel, and then stained with Coomassie Brilliant Blue. In a typical experiment, 1 ml of the soluble fraction of lysed induced cells was loaded onto 0.1 ml of the affinity matrix.

5 Purification using the His-tag was also carried out in an analogous manner to the streptavidin binding peptide-tag procedure with the same amounts of cells and in the same volumes. The soluble fraction was prepared in His-tag binding buffer (300 mM NaCl, 50 mM sodium phosphate, 0.25% Triton X-100, 10 mM imidazole, pH 8.0). The sample was applied directly to the Ni-column (Ni-NTA, 10 Qiagen, Valencia CA) and then incubated at 4°C for 30 minutes. The matrix was then washed with 40 column volumes of the same buffer containing 20 mM imidazole and then eluted with 3 successive 2 column volume aliquots of the same buffer containing 250 mM imidazole for 10 minutes each. Samples were analyzed as described above.

15 Purification using the maltose-binding protein sequence was carried out in an analogous manner to the streptavidin binding peptide-tag procedure with the same amounts of cells and in the same volumes. The soluble fraction was prepared in maltose-binding protein binding buffer (200 mM KCl, 20 mM HEPES, 10 mM 2-mercaptoethanol, 0.25% Triton X-100, pH 7.4). The sample was applied directly to the amylose column (New England Biolabs, Beverly MA) and then incubated at 4°C for 30 minutes. The matrix was then washed with 40 column volumes of the same buffer and then eluted with 3 successive 2 column volume aliquots of the same buffer containing 10 mM maltose for 10 minutes each.

20 For detection, ten picomoles of the loaded and eluted samples from the immobilized streptavidin column, the Ni-column, and the amylose column was loaded onto a 12% SDS-Tricine PAGE gel. In the adjacent lane, a whole bacterial extract from BL21 (DE3) cells was loaded. The whole cell extract was prepared by growing the cells to saturation in LB, removing the media by centrifugation, and re-suspending them in 10% of the original culture volume with the SDS-

PAGE protein-loading buffer. Six microliters of this extract was run on the gel. These two samples and a molecular weight marker were run side by side on the gel in duplicate. After running the gel, it was stained with Coomassie Brilliant Blue

This gel is shown in Figure 13. A band of the correct size was purified 5 using each of the three columns. Purification on immobilized streptavidin gave the highest purity sample. No other bands were visible by Coomassie Brilliant Blue-stained SDS-Tricine PAGE gel analysis. At least one impurity was detected in the Ni-NTA-purified sample, and several contaminants were apparent in the amylose-purified sample. These results suggest that the streptavidin binding peptide-tag 10 provides superior purity after a single purification step from lysed induced cells.

Detection of Fusion Proteins Containing Streptavidin Binding Peptides Using  
Streptavidin-Derived Reagents

Recombinant proteins containing streptavidin affinity tags may also be detected using reagents that bind to these affinity tags. A wide range of 15 streptavidin-derivatized reagents is commercially available, and as a consequence the streptavidin binding peptide-tag provides a versatile detection tool. To demonstrate the utility of this interaction, an experiment was performed in which a recombinant protein was probed with streptavidin-derivatized horseradish 20 peroxidase.

In this experiment the multiply-tagged protein was purified on the streptavidin column. The purified protein and an *E. coli* cell lysate were electrophoresed in adjacent lanes of a SDS-Tricine PAGE gel as described above. The protein on the gel was transferred to nitrocellulose (Trans-blot transfer 25 medium, 0.2  $\mu$ m, Biorad catalog number 162-0112) at 10 V for 30 minutes using the manufacturer's instructions (Trans-blot semi-dry transfer cell, Biorad catalog number 170-3940). Efficient protein transfer was confirmed by the presence of the pre-stained molecular weight markers on the nitrocellulose.

After transfer, the nitrocellulose was incubated in TBS (25 mM TrisHCl, 138 mM NaCl, 2.68 mM KCl, pH 7.4) plus 0.05% Polyoxyethylene-sorbitan monolaurate (Tween-20) and 3% BSA for 1 hour at room temperature. The blot was then briefly rinsed with the same buffer without BSA, and then a streptavidin-  
5 derivatized horseradish peroxidase conjugate (Amersham-Pharmacia, product number RPN1231) was added at a 1,000-fold dilution in TBS/0.05% Tween-20/3% BSA, and allowed to incubate for 1 hour at room temperature. The blot was then washed 3 times with TBS/0.05% Tween-20, and then one time with TBS.  
10 The HRP substrate (3,3',5,5'-tetramethylbenzidine, Promega catalog number W4121) was then added according to the manufacturers instructions, and the blot was developed for approximately 1 minute.

These results are shown in Figure 14. The streptavidin binding peptide-tagged protein is readily observed, and no proteins from the *E. coli* lysate are labeled, thus indicating the specificity of this interaction. Streptavidin-derivatized horseradish peroxidase and other streptavidin-derivatized reagents therefore provide many alternative methods of detecting streptavidin binding peptide-tagged proteins on membranes, plates, tissue sections, et cetera.

#### Yield of Fusion Proteins Containing Streptavidin-Binding Peptides

When scaling up protein expression to one milligram and above, the capacity and expense of the affinity matrix often begins to become important. To measure the capacity of the three matrices described above for their respective tag sequences, each matrix was overloaded with the multiply-tagged protein. Cells over-expressing this protein were split into three aliquots and re-suspended in different buffers according to the matrix that was to be used. The sample applied to immobilized streptavidin was extracted into streptavidin-binding buffer, and the samples for the other two purifications were extracted into the buffers recommended by the manufacturers of the two matrices, as described above.  
20  
25

The amount of protein in the flow-throughs, washes, and elution fractions was measured using the Bradford assay. We confirmed that each column was overloaded by observing the multiply-tagged protein in the flow-through fractions from each column. Purification using Ni-NTA agarose (His-tag/imidazole) 5 yielded 12 mg of protein per ml of matrix. The amylose column yielded 4.4 mg of protein per ml of matrix. The immobilized streptavidin column yielded 0.5 mg of protein per ml of matrix (0.53 mg/ml with a standard deviation of 0.07 mg/ml, n = 4). The overall capacity of immobilized streptavidin for the streptavidin binding peptide-tag was therefore lower than that of the Ni-NTA agarose or amylose 10 matrices for their respective tags, but significantly greater than that of immobilized antibody matrices for purifying proteins upon the basis of epitope tags.

#### Biacore Analysis of the Affinity of a Fusion Protein for Streptavidin

The SB19-C4 streptavidin-binding fusion protein was expressed and purified from *E. coli*. This fusion protein contained, from the amino- to carboxy- terminus, maltose-binding protein, the first 38 amino acids of the SB19-C4 sequence, and a hexahistidine tag (Fig. 9B, SEQ ID No. 41). The plasmid (Fig. 9A, SEQ ID No. 40) encoding this fusion protein was constructed using standard molecular biology techniques and used to express the fusion protein in *E. coli*. as described above. This fusion protein was purified from the *E. coli* extract using amylose resin to bind the maltose-binding protein portion of the fusion protein and then Ni-NTA resin to bind the hexahistidine tag.

To measure the affinity of the fusion protein for streptavidin, the fusion protein was immobilized on a biacore chip through the crosslinking of free amino 25 groups in the fusion protein to the biacore chip. Buffer containing streptavidin was washed over the chip, allowing streptavidin to bind the immobilized fusion protein (Fig. 10B). This resulted in an increase in the biacore response units which are proportional to the amount of streptavidin adhering to the biacore chip. Then buffer without streptavidin was washed over the chip, and the biacore response

units decreased as streptavidin dissociated from the immobilized fusion protein (Figs. 10A and 10B). To measure the association rate for the binding of streptavidin to the fusion protein, streptavidin concentrations of 1.6, 0.8, 0.4, 0.2, 0.1, or 0.05  $\mu$ M, (lines “a” to “f” in Fig. 10B, respectively) were washed over the 5 biacore chip. The buffer also contained 40 mM Tris(hydroxymethyl)aminomethane, 300 mM KCl, 2 mM EDTA, 0.1% w/v Triton X-100, and 5 mM 2-mercaptoethanol at pH 7.4. This data was used to calculate an 10 association rate,  $k_a$ , of  $5 \times 10^4$ /M/s, as described previously (BIACORE X Instrument Handbook, version AA, Biacore AB, Uppsala Sweden, 1997). To measure the dissociation rate, a pulse of 23, 11.5, or 5.75  $\mu$ M streptavidin in the buffer described above was administered, and then buffer without streptavidin was 15 washed over the chip (Fig. 10A). This data was used to calculate an upper limit of  $2 \times 10^3$ /s for the dissociation rate,  $K_D$  (BIACORE X Instrument Handbook, *supra*). Based on these calculated association and dissociation rates, the dissociation 20 constant,  $K_D$ , for the binding of streptavidin by this fusion protein was less than 40 nM. This result confirms the high affinity binding of the SB19-C4 peptide for streptavidin that was observed in the streptavidin column-binding assay and the EMSA assay (Table 1). Additionally, this result demonstrates that this peptide maintains its high affinity for streptavidin when expressed as part of a fusion protein.

#### Spin-filter Binding Inhibition Assay Analysis of the Affinity of a Fusion Protein for Streptavidin

To measure the  $K_D$  of the peptide described above, a second and more 25 general method, termed a Spin-filter Binding Inhibition Assay (SBIA), was also utilized. This method is especially appropriate for cases in which numerous proteins or peptides are derived from *in vitro* selection techniques using immobilized targets such as phage display (Smith, G. P. *et al. Chem. Rev.* 97:391-410, 1997), mRNA display (Roberts *et al. Proc. Natl. Acad. Sci. USA* 94:12297-

12302, 1997; Liu *et al.* *Methods Enzymol.* 318:268-293, 2000; Keefe *et al.* *Current Protocols in Molecular Biology* 2001; Keefe *et al.* *Nature* 410:715-718, 2001) or ribosome display (Jermutus *et al.* *Curr. Opin. Biotechnol.* 9:391-410, 1998). The principal benefit of this method is that it allows the affinities and specificities of interacting proteins to be assayed before investing the time required to over-express and purify them in the quantities required for conventional affinity determinations.

In general, SBIA utilizes low concentrations ( $<K_D$ ) of  $^{35}\text{S}$ -labeled protein generated in a cell-free translation system. The labeled protein is exposed to the bead-immobilized target (in this case immobilized streptavidin), and then the flow-through is collected by centrifugation in a  $0.2\ \mu\text{m}$  Durapore® spin-filter. The fraction of counts that pass through the filter (and therefore did not bind to the column) indicates the fraction of labeled peptide that did not bind to the matrix. To determine the affinity of the interaction, the labeled protein is first exposed to a range of concentrations of non-immobilized target. After this mixture has reached equilibrium, it is briefly (1 minute) exposed to the bead-immobilized target, and then spin-filtered as above. The initial incubation with the soluble target will compete with the binding of the radio-labeled protein to the immobilized target. The amount of inhibition is directly related to the fraction of labeled protein that was bound to the free target before this mixture was exposed to the immobilized target. By plotting the immobilized target-binding inhibition against the concentration of the free target, the  $K_D$  can easily be derived.

Because this titration is based on the interaction of the protein with the free (not immobilized) target, it may be more accurate than methods that quantify peptide binding to immobilized targets. However, SBIA may underestimate the affinity if there is significant dissociation of the complex during the brief incubation with immobilized target. The  $K_D$  corresponds to the concentration of free target that half-inhibits the binding to the immobilized target. As long as the concentration of the labeled binder is significantly lower than the  $K_D$ , the

concentration of free target may be approximated as the total concentration of added target. This method may be generally useful for the determination of  $K_D$  values for protein-protein, protein-peptide, and protein-small molecule complexes.

To measure the  $K_D$  of the SB19-C4 peptide, this peptide was fused to a  
5 FLAG-tag (streptavidin binding peptide-FLAG) (Wilson *et al. Proc. Natl. Acad. Sci. USA* 98:3750-3755, 2001). Streptavidin binding peptide-FLAG was then translated in the presence of  $^{35}$ S-labeled methionine by *in vitro* translation in reticulocyte lysate according to the manufacturer's instructions (Red Nova, Novagen, Madison, WI) using a template concentration of 400 nM, 1 mM extra  
10  $MgCl_2$  and 100 mM extra KCl. This mixture was then purified successively upon the basis of the FLAG-tag and then the His-tag (using the manufacturer's instructions; denaturing conditions were used for the Ni-NTA purification). The resultant purified peptide was then dialyzed into streptavidin-binding buffer (SBB: 300 mM KCl, 40 mM Tris(hydroxymethyl) amino methane, 5 mM 2-mercaptoethanol, 2 mM EDTA, 0.1% Triton-X 100, pH 7.4). The peptide was then diluted into the same buffer and mixed with a range of different streptavidin concentrations to give a set of 50  $\mu$ l samples in which the SB19-FLAG peptide was at 200 pM and the streptavidin concentration ranged from 30 pM to 1  $\mu$ M.  
15 Each of these samples was then incubated for 2 hours at 0°C and then subsequently incubated for 1 minute with 10  $\mu$ l samples of the washed and dried immobilized streptavidin matrix (Ultralink Immobilized Streptavidin Plus, Pierce, Rockford IL). The flow-throughs were then immediately collected by centrifugation in a 0.2  $\mu$ m Durapore® spin-filter (Millipore, Bedford MA), and these were counted in a  
20 scintillation counter. These data were iteratively fitted to the following equation  $y = b + c(K_D/(K_D + x))$  in which  $y$  was the number of radioactive decompositions detected per minute in each flow-through,  $K_D$  is the dissociation constant of the complex,  $x$  was the concentration of free streptavidin,  $b$  was the number of counts per minute not competent to bind the matrix under the assay conditions, and  $c$  was the number of counts per minute competent to bind the matrix under the assay  
25

conditions.  $K_D$ , b, and c were iteratively determined using the program Deltagraph 4.0 (SPSS, Chicago IL).

In this experiment, the binding of labeled streptavidin binding peptide-tagged peptide was inhibited by pre-incubation with free streptavidin (Figure 12). In this experiment 48% of the counts bound to immobilized streptavidin in the 1 minute slurry incubation in the absence of free streptavidin competitor, and this binding was completely inhibited by high concentrations (>100nM) of streptavidin. Analysis of the binding curve gave a  $K_D$  of 2.5 nM, which compared very favorably with the  $K_D$  determined by other methods. For example, the same peptide was purified on a FLAG-affinity matrix, then bound to streptavidin immobilized on a microtiter plate. The labeled streptavidin binding peptide-tagged peptide was incubated with a range of streptavidin concentrations for 1 hour before being transferred to a streptavidin-coated plate and incubated for five minutes. The labeled peptide not bound to the plate was pipetted off. The binding affinity was measured by competition with varying concentrations of streptavidin. Analysis of the binding curve gave a  $K_D$  of 2.4 +/- 0.1 nM. (Figure 15)(2.4 nM; Wilson *et al. Proc. Natl. Acad. Sci. USA* 98:3750-3755, 2001). The streptavidin binding peptide-tag therefore bound to streptavidin with a ~5,000-fold higher affinity than does the Strep-tag II (Schmidt *et al. J. Mol. Biol.* 255:753-66, 1996). This higher affinity accounts for the fact that, after extensive washing (with 80 column volumes), the yield of retained peptide using the streptavidin binding peptide-tag was 2,200-fold higher than the yield using the Strep-tag II (Wilson *et al. Proc. Natl. Acad. Sci. USA* 98:3750-3755, 2001). Both the streptavidin binding peptide-tag and the Strep-tag II contain the tripeptide motif HPQ, but the flanking sequence in the streptavidin binding peptide-tag presumably provides additional favorable contacts with streptavidin.

#### Other Embodiments

From the foregoing description, it will be apparent that variations and modifications may be made to the invention described herein to adopt it to various usages and conditions. Such embodiments are also within the scope of the following claims.

5 All publications mentioned in this specification are herein incorporated by reference to the same extent as if each independent publication or patent application was specifically and individually indicated to be incorporated by reference.

10

What is claimed is:

1. A method for preparing a poly(ether sulfone) polymer, comprising: